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Lipids, lipoprotein distribution and depressive symptoms: the
Multi-Ethnic Study of Atherosclerosis
KL Ong1, MJ Morris1, RL McClelland2, J Maniam1, MA Allison3 and K-A Rye1
Previous studies suggest lower concentrations of total and high-density lipoprotein (HDL) cholesterol to be predictive of
depression. We therefore investigated the relationship of lipids and lipoprotein distribution with elevated depressive symptoms
(EDS) in healthy men and women from the Multi-Ethnic Study of Atherosclerosis (MESA). Participants were followed up over a 9.5-
year period. EDS were defined as a Center for Epidemiological Studies Depression (CES-D) score ⩾ 16 and/or use of antidepressant
drugs. Lipoprotein distribution was determined from plasma using nuclear magnetic resonance spectroscopy. Among 4938 MESA
participants (mean age = 62 years) without EDS at baseline, 1178 (23.9%) developed EDS during follow-up. In multivariable Cox
regression analyses, lower total, low-density lipoprotein (LDL) and non-HDL cholesterol concentrations at baseline were associated
with incident EDS over 9.5 years (hazards ratio (HR) = 1.11–1.12 per s.d. decrease, all Po0.01), after adjusting for demographic
factors, traditional risk factors including LDL cholesterol, HDL cholesterol and triglycerides. Lipoprotein particle subclasses and sizes
were not associated with incident EDS. Among participants without EDS at both baseline and visit 3, a smaller increase in total or
non-HDL cholesterol between these visits was associated with lower risk of incident EDS after visit 3 (HR = 0.88–0.90 per s.d.
decrease, Po0.05). Lower baseline concentrations of total, LDL and non-HDL cholesterol were significantly associated with a higher
risk of incident EDS. However, a short-term increase in cholesterol concentrations did not help to reduce the risk of EDS. Further
studies are needed to replicate our findings in cohorts with younger participants.
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INTRODUCTION
Previous studies have suggested a possible relationship between
dyslipidemia and depression. In a study of 29 133 men aged 50–69
years in Finland with a follow-up period of 5–8 years, a low serum
total cholesterol concentration at baseline was associated with
major depression and death from suicide.1 However, this study
assessed total and high-density lipoprotein (HDL) cholesterol
concentrations only. In another recent study of 2187 Australian
men aged 81.6 (s.d. 3.6) years, a lower plasma HDL cholesterol
concentration, but not low-density lipoprotein (LDL) cholesterol
concentration, was associated with higher risk of depression after
5 years.2 These studies are limited by their analysis of data in men
only, and a lack of comprehensive assessment of different lipid
measures.
As the precise link between lipid profile and depression is not
well established, longitudinal studies in other settings are needed
to strengthen the evidence for a causal relationship. Moreover, it is
not known whether there is any difference in such a relationship
across subgroups of subject characteristics, especially race/
ethnicity, sex and baseline cholesterol concentration.
As lipoprotein particle subclass and size have been demon-
strated to affect cardiovascular risk independent of conventional
measures of plasma lipids (such as total cholesterol, HDL
cholesterol, LDL cholesterol and triglyceride concentrations), it is
possible that lipoprotein distribution may also be related to
depression, independent of plasma cholesterol concentrations.
Therefore, in the current study we investigated the longitudinal
relationship of plasma lipid concentrations and lipoprotein
distribution at baseline with the development of elevated
depressive symptoms (EDS) in apparently healthy participants
from the Multi-Ethnic Study of Atherosclerosis (MESA).
MATERIALS AND METHODS
Participants
The MESA study is a multicenter, community-based cohort study on the
prevalence, correlates and progression of subclinical cardiovascular disease
(CVD). It consists of 6814 men and women of four major ethnic groups
(Caucasian, African American, Hispanic American and Chinese American)
who were 45–84 years old and free of clinically apparent CVD at baseline.3
They were recruited from six US communities (Baltimore, MD; Chicago, IL;
Forsyth County, NC; Los Angeles County, CA; New York, NY; and St Paul,
MN) between July 2000 and August 2002. Each field site was recruited
from locally available sources, which included lists of residents, lists of
dwellings and telephone exchanges. In the last few months of the
recruitment period, supplemental sources (lists of Medicare beneficiaries
from the Centers for Medicare and Medicaid Services and referrals by
participants) were used to ensure inclusion of adequate numbers of
minority and elderly subjects. Although the cohort was community-based,
sampling was performed in a manner that provided balanced recruitment
across strata defined by gender, ethnicity and age group (45–54, 55–64,
65–74 and 75–84 years) and was not designed to represent the
demographic distribution of the source communities. Selection from the
sampling frames differs by site. In three Field Centers (Forsyth County, New
York, Chicago), random samples, stratified by age and gender, were
selected from the sampling frames. In the others (St Paul, Baltimore, Los
Angeles) the sampling frame did not contain demographic information
and recruitment was along geographic boundaries (St Paul, Baltimore) or
1School of Medical Sciences, University of New South Wales Australia, Sydney, NSW, Australia; 2Department of Biostatistics, University of Washington, Seattle, WA, USA and
3Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. Correspondence: Dr KL Ong, School of Medical Science, University of New
South Wales Australia, Sydney, NSW 2052, Australia.
E-mail: oklws@yahoo.com.hk
Received 20 May 2016; revised 12 September 2016; accepted 4 October 2016
Citation: Transl Psychiatry (2016) 6, e962; doi:10.1038/tp.2016.232
www.nature.com/tp
by random digit dialing (Los Angeles) to target areas. Participant exclusion
criteria included age o45 or484 years, physician-diagnosed CVD, current
atrial fibrillation, having undergone procedures related to CVD, active
treatment for cancer, pregnancy, any serious medical conditions that
would prevent long-term participation, weight 4300 pounds, cognitive
inability, living in or waiting for a nursing home, plans to leave the
community within 5 years, language barrier and chest CT scan in the past
year. Participants were followed up in person at four clinic visits over a
follow-up period of 8.0–11.4 years (mean= 9.5 years). The study was
approved by the institutional review boards at all participating centers and
informed written consent was obtained from all participants. The study
was performed in compliance with the principles of the Declaration of
Helsinki. Details of the study objectives, design and protocol have been
described previously3 and are available at http://www.mesa-nhlbi.org.
Among 6814 participants at baseline, valid data on EDS at both baseline
and follow-up were available on 6124 participants, of whom 5018
participants did not have EDS at baseline. Out of the 5018 participants,
5000 had their lipoprotein profile measured by nuclear magnetic
resonance spectroscopy. After further excluding participants with missing
data on conventional measurement of lipids (for example, LDL cholesterol,
HDL cholesterol and triglycerides), a total of 4938 participants were
included in the analysis.
Assessment of depressive symptoms
Using the Center for Epidemiological Studies Depression Scale (CES-D),
depressive symptoms were assessed by a self-report at visits 1, 3, 4 and 5.
CES-D is a 20-item questionnaire developed to assess depressive
symptoms in community.4 The CES-D items represent the major
components of depression and include depressed mood, feelings of
worthlessness, feelings of hopelessness, loss of appetite, poor concentra-
tion and sleep disturbance. Although the CES-D is not an assessment of
clinical depression, a CES-D score ⩾ 16 has been found to be consistent
with at least mild-to-moderate depression or dysthymia.5 Data on the use
of antidepressant drugs (tricyclics, nontricyclics and monoamine oxidase
inhibitors) were also collected in visits 1–5. In this study, EDS was defined
as a CES-D score ⩾ 16 and/or use of antidepressant drugs (as described
previously in other MESA studies).6,7 In a sensitivity analysis, we repeated
the analysis with EDS defined as a CES-D score of (a) ⩾ 21 or self-reported
use of antidepressant medications and (b) ⩾ 16 only.6 A CES-D score of
⩾ 21 has been considered as a clinical cut-point to indicate probable major
depression.8
Conventional measures of lipids
Venous blood samples were collected after a 12-h fast by certified
technicians using standardized venipuncture procedures. Samples were
then centrifuged at 2000 g for 15 min at 4 °C within 30 min of collection.
EDTA plasma samples were aliquoted on ice, stored at − 70 °C and then
shipped on dry ice to the MESA central laboratory for measurement of lipid
levels. HDL cholesterol was measured using the cholesterol oxidase
method (Roche Diagnostics, Indianapolis, IN, USA) after precipitation of
non-HDL cholesterol with magnesium/dextran sulfate. Triglyceride con-
centrations were measured using a glycerol-blanked enzymatic method
with the Triglyceride GB reagent (Roche Diagnostics) on the Roche COBAS
FARA centrifugal analyzer. The laboratory coefficient of variations (CVs) for
total cholesterol, HDL cholesterol and triglycerides were 1.6%, 2.9% and
4.0%, respectively. In plasma samples having a triglyceride value
o400 mg dl− 1, LDL cholesterol was calculated using the Friedewald
formula.9 The two atherogenic indices, total/HDL cholesterol ratio and LDL/
HDL cholesterol ratio were also calculated.
Measurement of lipoprotein profile
The concentrations of lipoprotein particle subclasses in the entire cohort
were measured at baseline by LipoScience (Raleigh, NC, USA) with nuclear
magnetic resonance spectroscopy using the LipoProfile-3 algorithm as
described previously.10–13 Lipoprotein particles were classified as HDL, LDL,
intermediate-density lipoprotein (IDL) and very-LDL (VLDL) according to
their diameters, with HDL subclassified as small, medium and large; LDL
subclassified as small and large; and VLDL subclassified as small, medium
and large (Supplementary Table S1). The mean lipoprotein particle sizes
were the weighted average of the related subclasses. The CVs for the
particle concentrations of VLDL (VLDL-P), LDL (LDL-P) and HDL (HDL-P)
were all o4%. CVs for individual subclasses (large VLDL-P, medium VLDL-
P, small VLDL-P, small LDL-P, large LDL-P, large HDL-P and small HDL-P)
were o10%. CVs for IDL-P and medium HDL-P were 27.5%. CVs for the
mean VLDL-P, LDL-P and HDL-P size were o2.0%.
Other variables of interest
Information on age, race/ethnicity, education, marital status, smoking,
alcohol use, physical activity, total gross family income and self-reported
cancer were obtained using standardized questionnaires. The participant
was asked to bring to the clinic containers for all medications used during
the 2 weeks before the visit. The interviewer then recorded the name of
each medication, the prescribed dose and frequency of administration
from the containers. Physical activity was measured as the total number of
hours of moderate and vigorous activity per week, multiplied by metabolic
equivalent level.14
Participants wore light clothing and no shoes for measurement of height
and weight. Body mass index (BMI) was measured as the weight in
kilograms divided by height in meters squared. A standard flexible tape
measure was used to measure hip and waist circumferences. Resting blood
pressure was measured three times in a seated position with a Dinamap
model Pro 100 automated oscillometric sphygmomanometer (Critikon,
Tampa, FL, USA). The average of the last two blood pressure readings was
used in the analysis.
Hypertension was defined as blood pressure ⩾ 140/90 mm Hg or use of
antihypertensive medications. Diabetes was defined as fasting glucose
⩾ 126 mg dl− 1 or use of glucose-lowering medications. C-reactive protein
(CRP) was measured by immunonephelometry using a BNII nephelometer
(N High Sensitivity CRP; Dade Behring, Deerfield, IL, USA). The assay range
is 0.175–1100 mg l− 1. Intra-assay CVs range from 2.3 to 4.4% and inter-
assay CVs range from 2.1 to 5.7%. Fibrinogen antigen was measured using
the BNII nephelometer (N Antiserum to Human Fibrinogen; Dade Behring).
The intra-assay and inter-assay CVs are 2.7% and 2.6%, respectively.
Interleukin-6 (IL-6) was measured using ultrasensitive enzyme-linked
immunosorbent assay (Quantikine HS Human IL-6 Immunoassay; R&D
Systems, Minneapolis, MN, USA) with a CV of 6.3% and a detection range of
0.156–10.0 pg ml− 1. Estimated glomerular filtration rate was calculated
using the creatinine-based Chronic Kidney Disease Epidemiology Colla-
boration equation.15 Serum creatinine was measured by rate reflectance
spectrophotometry using thin film adaptation of the creatine amidino-
hydrolase method on the Vitros analyzer (Johnson & Johnson Clinical
Diagnostics, Rochester, NY, USA) with a CV of 2.2%. The reference range
in adult females was 0.4–1.1 mg dl− 1 and in adult males was
0.5–1.2 mg dl− 1.
Statistical analysis
Data analysis was performed using SPSS 22 (IBM, Armonk, NY, USA) and
STATA 14.0 (StataCorp, College Station, TX, USA). Data were presented as
mean (s.d.) or percentage (number). For variables with a skewed
distribution, data were presented as the median (interquartile range)
and log-transformed before analysis. Comparison of baseline clinical
characteristics between two groups of participants was performed by
independent t-test for continuous variables and Χ2-test for categorical
variables, respectively. Those variables with a Po0.2 were used as
covariates in subsequent regression analysis. As lipid-lowering medications
(statins, fibrates, niacin and/or bile-acid sequestrants) can affect lipid and
lipoprotein concentrations, lipid-lowering medication was adjusted for as a
covariate in all subsequent regression analyses.
The associations of conventional measures of lipids or lipoprotein
distribution (all as continuous variables) with the development of EDS at
follow-up events were assessed using Cox proportional hazard regression
analysis after adjustment for confounding factors. In this analysis, for each
participant who developed EDS, the time to event (having EDS) was
considered as the time interval between the date of the visit at which EDS
was ascertained and the date of baseline visit 1. For participants who
remained event-free, the follow-up time was censored at their last
available visit. The proportional hazards assumption was checked using
Schoenfeld residuals; we found violations for age and gender. Subsequent
exploratory analysis led to inclusion of age-squared in the model, and
treating the gender association as time-dependent (that is, the hazards
ratio (HR) for gender changes as a function of time). P for interaction was
estimated by including the multiplicative interaction term in the regression
models in the full sample after adjustment for the main effects of the
covariates. Multivariable linear regression analysis using robust s.e.
estimation was used to assess the association of plasma lipids at baseline
with absolute change in CES-D score between visits 1 and 5 among
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patients without EDS at baseline and self-reported use of antidepressant
medications at visit 5. In all regression analyses, replacement of BMI by
waist-to-hip ratio and height in the adjustment model made little
difference to the results (data not shown). No multicollinearity was
detected (variance inflation factorso4.0 in all the analyses). A two-tailed
Po0.05 was considered statistically significant.
RESULTS
Participant characteristics
The characteristics of the 4938 MESA-included participants and the
1876 excluded participants are shown in Supplementary Table S2.
Sixty-eight percent of the excluded participants had EDS at baseline
and 27% took antidepressant medications. Compared with these
excluded participants, the 4938 participants included in the analysis
were more likely to be male, more educated, married, physically
active and less obese, and with lower family income, prevalence
of diabetes and hypertension, circulating levels of inflammatory
markers. They were also less likely to be Hispanic American or current
smokers with less pack years of smoking.
Of the 4938 MESA participants without EDS at baseline, 1178
(23.9%) developed EDS over a mean follow-up period of 7.4 years.
As shown in Table 1, participants who developed EDS were more
likely to be younger, female, Caucasian or Hispanic American, less
educated and current smokers with higher pack years of smoking,
lower family income, higher BMI, higher estimated glomerular
filtration rate and less likely to be married than those participants
who did not develop EDS.
Association of lipid and lipoprotein profile with incident EDS
Table 2 shows the lipid profile of participants with and without
development of EDS during the follow-up period among 4938
participants without EDS at baseline. Participants with incident
EDS had slightly, but statistically significantly, lower concentra-
tions of total, LDL and non-HDL cholesterol, and lower athero-
genic indices (total/HDL cholesterol ratio and LDL/HDL cholesterol
ratio) than those who did not develop EDS. Participants with
incident EDS also had a slightly lower concentration of IDL-P.
In multivariable Cox regression analysis, lower concentrations of
total, LDL and non-HDL cholesterol, as well as lower atherogenic
indices, were significantly associated with a higher risk of incident
EDS (HRs = 1.10–1.12 per s.d. decrease; model 3, Table 3). Among
different lipoprotein subclass concentrations and sizes, a lower
concentration of large HDL-P was significantly associated with a
lower risk of incident EDS (model 3, Table 3). The association of
lower concentrations of total cholesterol (HR (95% confidence
interval (CI)) = 1.11 (1.03–1.19) per s.d. decrease, P= 0.004), LDL
cholesterol (HR (95% CI) = 1.10 (1.03–1.17) per s.d. decrease,
P= 0.004), non-HDL cholesterol (HR (95% CI) = 1.11 (1.03–1.19) per
s.d. decrease, P= 0.004), total/HDL cholesterol ratio (HR (95%
CI) = 1.11 (1.00–1.22) per s.d. decrease, P= 0.04) and LDL/HDL
cholesterol ratio (HR (95% CI) = 1.01 (1.01–1.19) per s.d. decrease,
P= 0.02) with a higher incident EDS risk remained significant after
further adjustment for large HDL-P concentration. However, the
associations of large HDL-P concentration with incident EDS risk
were not significant after further adjustment for total/HDL
cholesterol ratio or LDL/HDL cholesterol ratio (P= 1.00 and 0.96,
respectively). Similar results were obtained after excluding 786
(15.9%) participants taking any lipid-lowering medication at
baseline (data not shown).
Sensitivity analysis using alternative definition of incident EDS
In a sensitivity analysis, EDS was defined as a CES-D score of ⩾ 21
or self-reported use of antidepressant medications. Using this
definition, a total of 5236 participants without EDS at baseline
were included in the analysis using the same subject exclusion
criteria as before. Of these, 909 (17.4%) developed EDS during the
follow-up period. As shown in Supplementary Table S3, lower
concentrations of total, LDL and non-HDL cholesterol, and lower
ratios of total/HDL cholesterol and LDL/HDL cholesterol at
baseline, were significantly associated with a higher risk of
incident EDS after adjustment for confounding factors (all
Po0.01). No significant association was found for HDL cholesterol
and triglyceride concentrations or for the concentration and size
of different lipoprotein particle subclasses.
In a separate analysis, EDS was defined as a CES-D score of ⩾ 16
only, regardless of whether the participants took antidepressant
Table 1. Baseline clinical characteristics of participants with and
without EDS developed during follow-up
Characteristics Without EDS With EDS P
N 3760 1178 —
Age, years 62.3 (10.0) 61.2 (10.2) 0.001
Women, % 46.4 (1744) 58.1 (685) o0.001
Race/ethnicity, %
Caucasian 38.3 (1440) 41.2 (485) o0.001
African American 29.5 (1108) 24.7 (291)
Hispanic American 18.6 (698) 23.6 (278)
Chinese American 13.7 (514) 10.5 (124)
Education, %
oHigh school 14.2 (533) 19.4 (228) o0.001
High school 41.1 (1543) 43.3 (510)
4High school 44.7 (1680) 37.3 (439)
Smoking, %
Never 51.9 (1949) 48.2 (567) o0.001
Former 37.2 (1399) 36.8 (433)
Current 10.9 (409) 15.0 (177)
Pack years of smoking 10.4 (19.7) 12.2 (23.0) 0.01
Current alcohol use, % 57.6 (2155) 57.5 (675) 0.95
Total gross family income
o$30 000 31.7 (1150) 38.5 (439) o0.001
$30 000–$74 999 41.1 (1491) 40.2 (458)
⩾ $75 000 27.2 (985) 21.3 (243)
Marital status, %
Married 66.0 (2464) 60.4 (704) o0.001
Widowed/divorced/
separated
26.8 (1001) 30.0 (350)
Single 7.2 (268) 9.5 (111)
Physical activity, MET-hours
per weeks
98 (98) 97 (95) 0.72
BMI, kg/m2 28.0 (5.2) 28.5 (5.6) 0.02
Waist-to-hip ratio 0.927 (0.080) 0.924 (0.080) 0.17
Heart rate, beats per minute 62.6 (9.4) 63.1 (9.6) 0.08
Diabetes, % 10.9 (409) 12.1 (142) 0.27
Hypertension, % 42.8 (1610) 45.0 (530) 0.19
Self-reported cancer, % 8.0 (302) 6.7 (79) 0.13
Any lipid-lowering
medication, %
15.8 (595) 16.2 (191) 0.75
CRP, mg l− 1 a 1.79 (0.80–
4.02)
1.90 (0.84–
4.12)
0.53
Fibrinogen, mg dl− 1 344 (72) 344 (72) 0.87
IL-6, pg ml− 1 a 1.15 (0.75–
1.83)
1.14 (0.75–
1.73)
0.16
eGFR, ml min−1 1.73 m− 2 77.6 (15.9) 79.3 (16.0) 0.002
Abbreviations: BMI, body mass index; CRP, C-reactive protein; EDS, elevated
depressive symptoms; eGFR, estimated glomerular filtration rate; IL-6,
interleukin-6; MET, metabolic equivalent. Data are expressed as mean
(s.d.), percent (n) or median (interquartile range), where appropriate.
P-values were estimated by t-test for continuous variables and Χ2-test
for categorical variables, respectively. aP-values were estimated using
ln-transformed data.
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medications. Using this definition, a total of 5274 participants
without EDS at baseline were included in the analysis using the
same subject exclusion criteria as before. Of these, 991 (18.8%)
developed EDS during the follow-up period. As shown in
Supplementary Table S4, lower concentrations of total, LDL and
non-HDL cholesterol were associated with a higher risk of incident
EDS (all Po0.05). No significant association was found for other
lipid measures and concentrations and size of different lipoprotein
particle subclasses.
Subgroup analysis
As total, LDL and non-HDL cholesterol concentrations showed
significant association with incident EDS in the sensitivity analysis,
subsequent analysis focused on these three lipid measures. In
subgroup analysis, the associations of lower concentrations of
total, LDL and non-HDL cholesterol with higher incident EDS risk
(defined as CES-D score of ⩾ 21 or self-reported use of
antidepressant medications) did not differ significantly across
different subgroups of age, sex, race/ethnicity, BMI, conventional
lipid measures, atherogenic indices and CES-D score at baseline
(all P-values for interactions 40.05, Supplementary Table S5).
Association of conventional lipid measures with absolute change
in CES-D score between exams 1 and 5
Of the 4938 participants without EDS at baseline, 3485 had valid
data on CES-D score in the absence of antidepressant medication
at both visits 1 and 5. Their mean CES-D score increased by 1.6 (s.
d. 6.3) from 5.1 (s.d. 4.1) at visit 1 to 6.7 (s.d. 6.4) at visit 5. As
shown in Table 4, lower concentrations of total, LDL and non-HDL
cholesterol at baseline were significantly associated with an
increase in CES-D score during the follow-up period. No significant
interaction with race/ethnicity and sex was found.
Association of changes in conventional lipid measures with
subsequent risk of incident EDS
There were 3919 participants with valid data on lipid profile who did
not have EDS (CES-D score of ⩾16 or self-reported use of
antidepressant medications) at both baseline visit 1 and visit 3 (a
mean period of 3.2 years), and had valid data on incident EDS after
visit 3. Among these 3919 participants, 576 people (14.7%)
developed incident EDS over a mean follow-up period of 6.3 years
after visit 3. As shown in Table 5, a smaller absolute or relative
increase in total cholesterol and non-HDL cholesterol concentrations
between baseline visit 1 and visit 3 was associated with a lower risk
of incident EDS after visit 3 (HRs=0.88–0.90 per s.d. decrease, all
Po0.05). No significant interaction was found with age, sex, race/
ethnicity, BMI, conventional lipid measures and CES-D score at
baseline (data not shown). Similar results were found when analysis
was only performed among a subgroup of 2788 participants who did
not take any lipid-lowering medication at both visits 1 and 3 (data
not shown) or among a subgroup of 2824 participants not being
treated with a statin at visits 1, 2 and/or 3 (Supplementary Table S6).
DISCUSSION
In this study, and over 9.5 years of follow-up, lower total, LDL and
non-HDL cholesterol concentrations at baseline were found to be
associated with higher risk for incident EDS, but not lipoprotein
subclasses or particle size. The association of lower concentrations
of total, LDL and non-HDL cholesterol at baseline with incident
EDS did not differ significantly across subgroups of age, sex, race/
ethnicity, BMI, baseline conventional measures of lipids and CES-D
score. Similar results were obtained when using a higher cutoff
point for the CES-D score (⩾21) to define EDS, when using CES-D
score (⩾16) only to define EDS, or when analyzing the changes in
CES-D score between baseline and last visit.
Some previous studies have reported a lower concentration of
total and LDL cholesterol in patients with depressive symptoms16–19
and incident depression.1,2 The relationship between metabolic
syndrome and markers such as serum cholesterol and mood is
complex. For both disorders, impaired serotonergic neurotransmis-
sion and inflammatory factors have been suggested to be involved.
Cholesterol has an important role in the central nervous system, and
it has been suggested that a lower serum total cholesterol
concentration may be associated with a decrease in cell membrane
cholesterol content.20 There is evidence that membrane cholesterol
can modulate activity of the serotonin transporter, SERT,21 which
controls the extracellular concentrations of serotonin, and that
altered brain serotonin uptake provides a plausible link between
cholesterol and changes in mood.22 There are some data supporting
this, with a trend for a negative correlation between auditory
processing (linked to serotoninergic neurotransmission) and serum
Table 2. Baseline lipid profile of participants with and without EDS
developed during follow-up
Lipid and lipoprotein
profile
Without EDS With EDS P
Conventional lipid measure
Total cholesterol,
mg dl− 1
193.5 (34.3) 192.8 (34.1) 0.02
LDL cholesterol,
mg dl− 1
118.2 (30.9) 115.7 (30.8) 0.003
HDL cholesterol,
mg dl− 1a
48 (40–58) 49 (41–60) 0.52
Non-HDL cholesterol,
mg dl− 1
143.0 (34.0) 140.9 (34.2) 0.01
Triglycerides,
mg dl− 1a
108 (77–155) 111 (77–160) 0.79
Total/HDL cholesterol
ratio
4.08 (1.17) 3.96 (1.15) 0.04
LDL/HDL cholesterol
ratio
2.52 (0.93) 2.41 (0.91) 0.01
Lipoprotein particle concentration
VLDL-P, nmol l− 1
Totala 62.1 (39.9–87.9) 63.2 (40.2–88.4) 0.58
Largea 2.4 (0.8–6.1) 2.6 (0.9–6.5) 0.70
Mediuma 23.4 (12.1–40.6) 23.8 (11.9–39.5) 0.60
Smalla 31.5 (19.6–44.8) 32.7 (20.4–45.4) 0.74
IDL-P, nmol l− 1a 102 (50–176) 103 (51–174) 0.04
LDL-P, nmol l− 1
Total 1131 (304) 1110 (317) 0.06
Large 584 (252) 602 (259) 0.89
Small 547 (374) 508 (375) 0.09
HDL-P, μmol l− 1
Total 33.7 (6.5) 34.6 (6.7) 0.18
Largea 5.0 (3.3–7.6) 5.3 (3.6–8.2) 0.14
Mediuma 12.2 (8.3–16.6) 12.8 (8.9–17.5) 0.62
Small 14.9 (5.5) 14.6 (5.8) 0.87
Lipoprotein particle size, nm
VLDL-P 48.2 (7.7) 48.5 (7.8) 0.93
LDL-P 20.7 (0.5) 20.8 (0.5) 0.75
HDL-P 9.2 (0.5) 9.3 (0.5) 0.10
Abbreviations: EDS, elevated depressive symptoms; HDL, high-density
lipoprotein; HDL-P, high-density lipoprotein particle; IDL-P, intermediate-
density lipoprotein particle; LDL, low-density lipoprotein; LDL-P, low-
density lipoprotein particle; VLDL-P, very-low-density lipoprotein particle.
Data are expressed as mean (s.d.) or median (interquartile range). P-values
were estimated by multivariable linear regression model with continuous
measures of lipid and lipoprotein profile as the dependent variable after
adjusting for age, sex and race/ethnicity. aP-values were estimated using
ln-transformed data.
Lipids and depressive symptoms
KL Ong et al
4
Translational Psychiatry (2016), 1 – 7
LDL in patients with major depressive disorder.23 Interestingly, rats
treated with the lipid-lowering medication, simvastatin, had evidence
of reduced SERT activity, based on platelet serotonin uptake, and
reduced membrane microviscosity, in addition to some behavioral
changes, relative to vehicle-treated control rats.24 It has also been
hypothesized that a low plasma cholesterol level may also reduce the
synthesis of neurosteroids,25 which are potent and effective
neuromodulators, leading to stress and other psychiatric disorders
such as anxiety, depression and aggressive mood disorders.26
The association of lower total cholesterol and depressive
symptoms is more consistently reported in elderly people.16,17 In
a recent study of young adolescents, a higher concentration of
total cholesterol was indeed found to be associated with a higher
EDS risk.27 In the present study, data were adjusted for age, and
subgroup analysis did not reveal a significant interaction with age.
Therefore, our study did not provide evidence that age is an
important effect-modifying factor, although our study comprised
middle and older age participants. For HDL cholesterol, a recent
Table 3. Associations of lower lipid and lipoprotein profiles at baseline with incident EDS
Lipid and lipoprotein profile s.d. Model 1 Model 2 Model 3
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Conventional lipid measure
Total cholesterol, mg d1− 1 34.2 1.08 (1.02–1.15) 0.008 1.10 (1.03–1.17) 0.003 1.12 (1.05–1.20) 0.001
LDL cholesterol, mg d1− 1 30.9 1.10 (1.03–1.16) 0.002 1.11 (1.04–1.18) 0.001 1.11 (1.04–1.18) 0.001
HDL cholesterol, mg d1− 1 14.7 1.01 (0.95–1.07) 0.78 0.99 (0.92–1.06) 0.77 1.00 (0.93–1.08) 0.97
Non-HDL cholesterol, mg d1− 1 34.1 1.08 (1.02–1.14) 0.01 1.10 (1.04–1.17) 0.002 1.12 (1.05–1.20) 0.001
Triglycerides, mg d1− 1 64.6 0.98 (0.92–1.03) 0.41 1.01 (0.95–1.08) 0.79 1.00 (0.94–1.07) 0.94
Total/HDL cholesterol ratio 1.17 1.05 (0.98–1.11) 0.16 1.08 (1.01–1.15) 0.03 1.11 (1.02–1.20) 0.01
LDL/HDL cholesterol ratio 0.93 1.06 (1.00–1.13) 0.05 1.09 (1.02–1.17) 0.01 1.10 (1.02–1.18) 0.01
Lipoprotein particle concentration
VLDL-P, nmol l− 1
Total 35.2 0.98 (0.93–1.05) 0.61 1.02 (0.95–1.08) 0.64 0.98 (0.89–1.07) 0.66
Large 5.4 0.98 (0.92–1.04) 0.49 1.01 (0.95–1.08) 0.69 1.07 (0.94–1.21) 0.30
Medium 21.3 0.98 (0.92–1.04) 0.56 1.00 (0.94–1.07) 0.90 0.99 (0.90–1.08) 0.76
Small 19.4 1.00 (0.94–1.06) 0.91 1.02 (0.96–1.08) 0.56 0.98 (0.92–1.05) 0.62
IDL-P, nmol l− 1 94.9 1.04 (0.98–1.11) 0.16 1.05 (0.99–1.12) 0.10 1.01 (0.93–1.09) 0.85
LDL-P, nmol l− 1
Total 308 1.05 (0.99–1.12) 0.09 1.07 (1.01–1.14) 0.03 0.99 (0.91–1.09) 0.88
Large 254 1.01 (0.95–1.08) 0.67 1.01 (0.94–1.07) 0.87 0.93 (0.85–1.02) 0.11
Small 375 1.04 (0.98–1.10) 0.24 1.06 (0.99–1.13) 0.08 1.05 (0.95–1.15) 0.33
HDL-P, μmol l− 1
Total 6.6 0.96 (0.90–1.02) 0.22 0.96 (0.90–1.03) 0.28 0.96 (0.87–1.06) 0.40
Large 3.4 0.97 (0.92–1.03) 0.39 0.95 (0.89–1.02) 0.14 0.86 (0.74–0.99) 0.04
Medium 6.8 1.00 (0.94–1.06) 0.95 1.00 (0.94–1.07) 0.98 1.01 (0.94–1.08) 0.75
Small 5.6 0.98 (0.92–1.04) 0.46 0.99 (0.93–1.05) 0.74 0.98 (0.92–1.05) 0.62
Lipoprotein particle size, nm
VLDL-P 7.8 0.98 (0.92–1.04) 0.54 1.01 (0.95–1.08) 0.68 1.06 (0.96–1.16) 0.20
LDL-P 0.5 1.01 (0.95–1.07) 0.75 0.99 (0.93–1.06) 0.76 0.98 (0.89–1.07) 0.62
HDL-P 0.5 0.96 (0.90–1.02) 0.20 0.93 (0.87–1.00) 0.05 0.92 (0.84–1.01) 0.07
Abbreviations: CI, confidence interval; EDS, elevated depressive symptoms; HDL, high-density lipoprotein; HDL-P, high-density lipoprotein particle; HR, hazards
ratio; IDL-P, intermediate-density lipoprotein particle; LDL, low-density lipoprotein; LDL-P, low-density lipoprotein particle; VLDL-P, very-low-density lipoprotein
particle. HR is expressed in terms of per s.d. decrease in each lipid measure. Model 1: adjusted for age, age-squared, sex (as both time-independent and
-dependent variables) and race/ethnicity. Model 2: Further adjusted for education, smoking, pack years of smoking, total gross family income, marital status,
any lipid-lowering medication (yes or no), body mass index, heart rate, hypertension, self-reported cancer, interleukin-6 and estimated glomerular
filtration rate. Model 3: Further adjusted for HDL cholesterol (except for total/HDL cholesterol ratio and LDL/HDL cholesterol ratio), LDL cholesterol (except for
total cholesterol, non-HDL cholesterol, total/HDL cholesterol ratio and LDL/HDL cholesterol ratio) and triglycerides, where appropriate.
Table 4. Associations of lower levels of conventional lipid measures at baseline with absolute change in CES-D score during follow-up
Conventional lipid measures β P P for interaction with race/ethnicity P for interaction with sex
Total cholesterol 0.051 0.02 0.34 0.53
LDL cholesterol 0.043 0.02 0.61 0.74
HDL cholesterola 0.002 0.94 0.17 0.45
Non-HDL cholesterol 0.049 0.02 0.71 0.70
Triglyceridesa −0.004 0.86 0.65 0.85
Abbreviations: CES-D, Center for Epidemiological Studies Depression Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Data are expressed as
standardized regression coefficient (β) per s.d. decrease in each lipid measure in multivariable linear regression with absolute change in CES-D score as the
dependent variable. Model 1: Adjusted for baseline CES-D score, age, sex, race/ethnicity, education, smoking, pack years of smoking, total gross family income,
marital status, body mass index, heart rate, hypertension, self-reported cancer, log-transformed interleukin-6, estimated glomerular filtration rate, log-
transformed HDL cholesterol, LDL cholesterol (except total cholesterol and non-HDL cholesterol) and log-transformed triglycerides, and history of lipid-
lowering medication usage at visits 1 and 5 (‘no use at both visits’, ‘use at visit 1, but no use at visit 5’, ‘no use at visit 1, but use at visit 5’ and ‘use at both visits’),
where appropriate. aP-values were estimated using log-transformed data.
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study has reported the association of a lower plasma HDL
cholesterol concentration with a higher risk of depression in
elderly men.2 However, we did not find any significant association
of HDL cholesterol concentration with incident EDS risk in the
present study. The discrepancy could be due to differences in
subject characteristics such as age, education level, use of lipid-
lowering medications and smoking status, as well as the use of
different variables being adjusted in the regression models, and
different tests for assessment of depressive symptoms.
Despite being associated with lower CVD risk, lower plasma
concentrations of total, LDL and non-HDL cholesterol at baseline
are associated with a modestly higher incident EDS risk in the
present study. On the other hand, depression has also been
suggested as a risk factor for CVD.28,29 This paradoxical relation-
ship could be confounded by other factors related to depression
and CVD. Possible confounding factors are systemic
inflammation,30 and the associated pro-atherogenic lipoprotein
profile.31 In a previous small study of 65 depressed patients and 33
healthy controls, the depressed patients had lower total and LDL
cholesterol concentrations, and higher levels of small, dense LDL
particles than the healthy controls, which may explain the
paradoxical relationship of low cholesterol concentration and
high CVD risk in depression.18 However, in the present study with
a much larger sample size, we did not find a significant
independent association between atherogenic indices and
lipoprotein profiles using nuclear magnetic resonance spectro-
scopy with incident EDS risk. We did not find a significant
difference in CRP and IL-6 levels between participants with and
without incident EDS. The association between lipids and incident
EDS risk remained significant in the full adjustment model
(including IL-6 as covariate). Therefore, our study does not support
an important role of inflammation in the modest association
between lipids and incident EDS. There is evidence of sex-specific
relationships in the literature. For instance, recent work linked
atherogenic indices with a faster rate of increase in depressive
symptoms in women only.32 In another Korean study of 15 073
men and 15 034 women, depressive symptoms were associated
with the metabolic syndrome in women only, but were inversely
associated with the hypertension component of the metabolic
syndrome in men.33 A similar trend was found in our study, in
which the association of lower total cholesterol concentration with
EDS risk was found only in men (HR= 1.15, P= 0.009), but not in
women (HR= 1.09, P= 0.07), although the sex interaction did not
reach statistical significance (Supplementary Table S5).
Although a lower baseline total cholesterol concentration was
found to be associated with higher incident EDS over the whole
follow-up period in the present study, an interesting and
contradictory result was found when we analyzed the relationship
of changes in lipid levels from baseline to visit 3 with subsequent
risk of incident EDS. In this analysis, a larger increase in total
cholesterol concentration was associated with a higher subse-
quent risk. We are unclear for the discrepancy in the findings
between baseline lipid levels and the changes in lipid levels over
initial 3.2 years of follow-up. Nevertheless, our study does not
provide support for reducing the risk of EDS by increasing total
cholesterol concentrations.
In a recent study of 24 216 postmenopausal women, the
association of lower LDL cholesterol with incident EDS was only
found in those without lipid-lowering therapy, but not in those with
lipid-lowering therapy.34 In this regard, statins are commonly used
to lower the concentration of total and LDL cholesterol. However,
we did not find any significant interaction with lipid-lowering
therapy or use of statin in the association of lower total, LDL and
non-HDL cholesterol concentrations with higher EDS risk (data not
shown). In fact, the relationship of the use of statins with depression
is inconsistent, with some studies showing that statins increase
depression risk,25,35 and others having the opposite effect.36–38
Further investigations are needed to elucidate this paradoxical
relationship between total cholesterol concentration and EDS.
Our study has the advantage of making use of data with a
longitudinal study design and good quality control of a large well-
characterized sample of clinically apparently healthy participants.
However, there are several limitations in our study. In our analysis,
participants were defined as having EDS if they reported the use
of antidepressant medications. However, these medications can
also be used for other conditions such as anxiety, eating disorders,
smoking cessation, insomnia, post-herpetic pain and migraines,
and the reasons for the use of antidepressant medications were
not recorded in the MESA study. This may lead to the apparently
high incident EDS rate. In a retrospective analysis of Georgia
Medicaid recipients, ~ 75% antidepressant recipients reported off-
label use of antidepressant medications.39 However, in the present
study, similar findings were obtained in a separate analysis when
EDS was defined using the CES-D score, without the use of data on
antidepressant medications. Moreover, the absolute differences in
blood lipid concentrations between participants with and without
incident EDS were modest and clinical interpretation should be
cautious. Our study may also suffer from false-positive findings
due to multiple comparisons. However, as different parameters of
conventional lipid measures, and lipoprotein particle concentra-
tions and sizes were highly correlated with each other, multiple
testing correction was not performed.
In conclusion, although lower baseline concentrations of total
cholesterol, LDL cholesterol and non-HDL cholesterol are modestly
associated with incident EDS, here a larger increase in total
cholesterol also predicted a modestly higher subsequent risk of
EDS. Further studies are needed to investigate whether our findings
can be found in other cohorts with younger participants, and the
underlying mechanisms of the contradictory relationship between
cholesterol concentrations and EDS. Nevertheless, the beneficial
cardiovascular effects of lipid-lowering by drugs such as statins
outweigh the potential small and modest effects on EDS. Our study
does not support increasing cholesterol levels to reduce EDS.
Table 5. Associations of smaller changes in conventional lipid
measures with subsequent risk of incident EDS (n= 3919)
Conventional lipid measure s.d. HR (95% CI) P
Absolute change, mg dl− 1
Total cholesterol 31.6 0.89 (0.80–1.00) 0.048
LDL cholesterol 29.0 0.90 (0.81–1.00) 0.06
HDL cholesterol 8.2 1.02 (0.93–1.12) 0.69
Non-HDL cholesterol 31.5 0.89 (0.79–0.99) 0.04
Triglycerides 52.4 0.95 (0.86–1.04) 0.28
Relative change, %
Total cholesterol 15.9 0.88 (0.80–0.99) 0.03
LDL cholesterol 25.8 0.92 (0.85–1.00) 0.054
HDL cholesterol 16.0 1.01 (0.92–1.10) 0.85
Non-HDL cholesterol 21.9 0.90 (0.81–0.99) 0.03
Triglycerides 43.0 0.92 (0.84–1.01) 0.08
Abbreviations: CI, confidence interval; EDS, elevated depressive symptoms;
HDL, high-density lipoprotein; HR, hazards ratio; LDL, low-density
lipoprotein. HR is expressed in terms of per s.d. decrease in the change
of each lipid measure from baseline visit 1 to visit 3. Data were adjusted for
age, age-squared, sex (as both time-independent and -dependent
variables), race/ethnicity, education, smoking, pack years of smoking, total
gross family income, marital status, body mass index, heart rate,
hypertension, self-reported cancer, interleukin-6, estimated glomerular
filtration rate, corresponding lipid levels at baseline visit 1, HDL cholesterol,
LDL cholesterol (except for total cholesterol and non-HDL cholesterol) and
triglycerides at visit 1, history of lipid-lowering medication usage at visits 1
and 3 (‘no use at both visits’, ‘use at visit 1, but no use at visit 3’, ‘no use at
visit 1, but use at visit 3’ and ‘use at both visits’), time between visit 1 and
visit 3, and change in weight from visit 1 to visit 3.
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